Eli Lilly and (LLY) 10-Q 2009 Q3 Quarterly report

EXHIBIT 12.    STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

(Unaudited)

Eli Lilly and Company and Subsidiaries
(Dollars in millions)

	Nine Months
	Ended
	September 30,			Years Ended December 31,
	2009			2008			2007			2006			2005			2004
Consolidated pretax income (loss) before cumulative effect of a change in accounting principle	$	4,220.6		$	(1,307.6	)	$	3,876.8		$	3,418.0		$	2,717.5		$	2,941.9
Interest1		234.5			276.5			322.5			344.8			245.7			162.9
Less interest capitalized during the period		(23.4	)		(48.2	)		(94.2	)		(106.7	)		(140.5	)		(111.3	)
Earnings (loss)	$	4,431.7		$	(1,079.3	)	$	4,105.1		$	3,656.1		$	2,822.7		$	2,993.5
Fixed charges	$	234.5		$	276.5		$	322.5		$	344.8		$	245.7		$	162.9
Ratio of earnings (loss) to fixed charges		18.9		NM2				12.7			10.6			11.5			18.4

NM — Not meaningful
1	Interest is based upon interest expense reported as such in the consolidated income statement and does not include any interest related to unrecognized tax benefits, which is included in income tax expense.
2	For such ratio, earnings were $1.31 billion less than fixed charges. The loss for the year ended December 31, 2008 included special charges related to the EDPA settlement of $1.48 billion and acquired in-process research and development expense of $4.69 billion associated with the ImClone acquisition, as described in the notes to the accompanying consolidated financial statements.